{"article_title": "FDA greenlights Bristol-Myers Squibb combination cancer immunotherapy treatment for melanomaMedCity News", "article_keywords": ["melanomamedcity", "fda", "cancer", "greenlights", "combination", "worlds", "yervoy", "search", "support", "immunotherapy", "drug", "prices", "patients", "treatment", "report", "care", "squibb", "bristolmyers", "palliative"], "article_url": "http://medcitynews.com/2015/10/bristol-myers-squibb-fda-approval-for-cancer-immunotherapy/", "article_text": "TOP STORIES\n\nA combination of cancer immunotherapy drugs Yervoy and Opdivo from Bristol-Myers Squibb secured FDA approval as a new drug cocktail for treating advanced melanoma, but are likely to get just as much attention for their cost:$250,000 for one year of treatment per patient. The FDA made its decision based on a Bristol-funded study that showed the regimen significantly shrank tumors in 60 percent of melanoma patients, compared with 11 percent of patients receiving Yervoy alone. \u2014 The Wall Street Journal\n\nLIFE SCIENCES\n\nEcelyx Therapeutics raised $40 million in a Series E round to support clinical trials for Metformin Delayed Release \u2014 a drug to support 40 percent of Type 2 diabetes patients who cannot use metformin due to contraindications or poor tolerability. \u2014 PR Newswire\n\nAspen Park Pharmaceuticals has licensed a drug to treat castration resistant prostate cancer. \u2014 Columbus Business Journal\n\nPAYERS-PROVIDERS\n\nCMS will pay less than 13 percent of what it owes insurers \u2014$2.9 billion \u2014 to support a program enshrined in the Affordable Care Act to protect insurers on the law\u2019s marketplaces from heavy losses or having to spike premiums due to uncertainty as the law gets under way. \u2014 The Hill\n\nMontana based Bozeman Health Services is suing the executive search service Gallaher MSA Search for failing to turn up in its background check felony convictions for its newly fired president and CEO. Kevin Pitzer was convicted in 1983 in federal court of three felony counts of theft for embezzling approximately $100,000 from an Iowa residential and daycare facility where he worked as an administrative assistance and bookkeeper from 1981 to 1983, according to the report. He was 23 years old at the time. \u2014 Beckers Hospital Review\n\nA new report card gives New England states top marks for palliative care but the South tends to score badly. \u2014 The Association to Adavance Palliative Care, National Palliative Care Center\n\nA Denver VA Hospital has become one of the world\u2019s most expensive hospitals, with a $1.6 billion price tag after running over budget. It needs another $625 million to finish the project. \u2014 The Washington Post\n\nTECHNOLOGY\n\nOctober 1 was the first day ICD-10 went into effect. It will probably take awhile before any major problems bubble to the surface but some media outlets had some fun with headlines, like this one: \u201d 70,000 ways to get sick or die\u201d \u2014 Bloomberg\n\nSome additional analysis on what happened to Better. \u2014 Telecare Aware\n\nThe first continuous fitness tracker for the water from Lifetrak claims users can get use it to track heart rate, among other things. \u2014 PR Newswire\n\nPOLITICS\n\nU.S. Senator Bill Cassidy, a Republican for Louisiana who is also a physician and a member of the health committee, called for a more sophisticated perspective on drug prices, although he totally agree specialty pharma prices are really high. \u2014 The Hill\n\nA LITTLE BIT EXTRA\n\nThe world\u2019s not ready for an app that claims to be a Yelp for people and no one has learned that lesson better than the people behind Peeple. \u2014 The Register", "article_metadata": {"description": "The newly approved therapy comes with a hefty price tag.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "The newly approved therapy comes with a hefty price tag.", "title": "Morning Read: Bristol-Myers Squibb gets FDA approval for combined cancer immunotherapy treatment", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/2015/10/Opdivo_1.jpg", "updated_time": "2015-10-02T11:53:45-04:00", "url": "http://medcitynews.com/2015/10/bristol-myers-squibb-fda-approval-for-cancer-immunotherapy/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/2015/10/Opdivo_1.jpg", "description": "The newly approved therapy comes with a hefty price tag.", "card": "summary", "title": "FDA greenlights Bristol-Myers Squibb combination cancer immunotherapy treatment for melanoma"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,Bristol Myers Squibb, immunotherapy, morning read, pharmaceuticals, , MedCity News", "article": {"section": "Daily", "tag": "pharmaceuticals", "published_time": "2015-10-02T07:55:22-04:00", "modified_time": "2015-10-02T11:53:45-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "article_summary": "\u2014 The Association to Adavance Palliative Care, National Palliative Care CenterA Denver VA Hospital has become one of the world\u2019s most expensive hospitals, with a $1.6 billion price tag after running over budget.\n\u2014 Beckers Hospital ReviewA new report card gives New England states top marks for palliative care but the South tends to score badly.\nTOP STORIESA combination of cancer immunotherapy drugs Yervoy and Opdivo from Bristol-Myers Squibb secured FDA approval as a new drug cocktail for treating advanced melanoma, but are likely to get just as much attention for their cost:$250,000 for one year of treatment per patient.\nThe FDA made its decision based on a Bristol-funded study that showed the regimen significantly shrank tumors in 60 percent of melanoma patients, compared with 11 percent of patients receiving Yervoy alone.\nSenator Bill Cassidy, a Republican for Louisiana who is also a physician and a member of the health committee, called for a more sophisticated perspective on drug prices, although he totally agree specialty pharma prices are really high."}